胃经口内镜下肌切开术后临床结局分类与管理的新国际方案
这项多中心回顾性研究纳入2015年9月至2023年11月因难治性胃轻瘫接受胃经口内镜下肌切开术(G-POEM)的482例患者,其中221例(46%)有术前和术后胃排空检查结果并被纳入分析。研究根据症状改善和胃排空指标将临床结局分为4种类型,发现1型临床应答最常见(56%),中位随访48个月期间临床失败率为60%。
要点
- 1型临床应答(临床成功且胃排空闪烁显像改善)最常见,占56%。
- 原发性临床失败(2型和4型)患者每日阿片类药物使用率为23%,高于1型和3型的7%(P = .032)。
- 1型应答组中,71%在接受幽门靶向治疗后重新获得临床成功,重复G-POEM是再治疗后临床成功的独立预测因素(比值比2.2;P = .02)。
核心结论
- 研究强调G-POEM术后胃排空闪烁显像评估对刻画临床应答的重要性。
- 1型应答者更可能从后续幽门靶向再治疗中获益,尤其是重复G-POEM干预。
研究设计与样本
- 多中心回顾性研究,纳入2015年9月至2023年11月因难治性胃轻瘫接受G-POEM的患者。
- 482例患者中221例(46%)具有术前和术后G-POEM胃排空检查结果并被纳入分析。
主要发现
- 1型临床应答(临床成功且胃排空闪烁显像改善)最常见,占56%。
- 4型(临床失败且胃排空闪烁显像无改善)占23%,2型(临床失败且胃排空闪烁显像改善)占15%,3型(临床成功且胃排空闪烁显像无改善)占6.7%。
- 原发性临床失败(2型和4型)患者每日阿片类药物使用率为23%,1型和3型为7%(P = .032)。
- 中位随访48个月期间总体临床失败率为60%,其中31%接受幽门靶向再治疗,7%接受胃神经刺激器植入。
- 1型应答组中,71%在接受幽门靶向治疗后重新获得临床成功,重复G-POEM是再治疗后临床成功的独立预测因素(比值比2.2;P = .02)。
关键数值与推荐
- 临床结局根据症状改善和胃排空指标分为4种类型:1型为临床成功且胃排空闪烁显像改善,2型为临床失败且胃排空闪烁显像改善,3型为临床成功且胃排空闪烁显像无改善,4型为临床失败且胃排空闪烁显像无改善。
临床怎么用
- 研究强调G-POEM术后胃排空闪烁显像评估对刻画临床应答的重要性。
- 作者认为1型应答者更可能从后续幽门靶向再治疗中获益,尤其是重复G-POEM干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Gastric peroral endoscopic myotomy (G-POEM) is an emerging treatment for gastroparesis, but clinical outcomes can be inconsistent; hence, it is vital to enhance our management strategies for patients with clinical failure. METHODS: This was a multicenter retrospective review of patients who underwent G-POEM for refractory gastroparesis from September 2015 to November 2023. Clinical outcomes and management post-G-POEM were assessed and categorized into 4 types based on symptom improvement and gastric emptying metrics. RESULTS: Of the 482 patients, 221 (46%) underwent evaluations with pre- and post-G-POEM gastric emptying tests and were included in the study. Type 1 clinical response (clinical success with improved gastric emptying scintigraphy [GES]) was the most common outcome, occurring in 56%. This was followed by type 4 (clinical failure with no GES improvement) at 23%, type 2 (clinical failure with improved GES) at 15%, and type 3 (clinical success with no GES improvement) at 6.7%. Patients with primary clinical failure (types 2 and 4) showed significantly higher daily opioid use at 23%, compared with 7% in types 1 and 3 (P = .032). Clinical failure overall was observed in 60% during a median follow-up of 48 months, with 31% managed by pylorus-directed retreatment and 7% with gastric neurostimulator placement. In the type 1 response group, clinical success was re-established in 71% following pylorus-directed therapies, with repeat G-POEM being an independent predictor of clinical success post-re-treatment (odds ratio, 2.2; P = .02). CONCLUSIONS: Our study highlights the importance of post-G-POEM GES assessments for characterizing clinical responses. Type 1 responders are more likely to benefit from subsequent pylorus-directed re-treatments, particularly repeat G-POEM interventions. CLINICALTRIALS: gov, Number: NCT04434781.
引用
- Ichkhanian Y, Salame M, Wo JM, et al. A New International Scheme for the Classification and Management of Clinical Outcomes Post-gastric Peroral Endoscopic Myotomy. Clin Gastroenterol Hepatol. 2025. PMID: 40378985. doi:10.1016/j.cgh.2025.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。